secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001558370-24-010529
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q2 net loss $56.3M; restructures to cut 65% of workforce, burn by $75M/yr
--------------------------------------------------------------------------------

- Net loss $56.3M ($1.16 EPS) vs $68.5M ($1.44 EPS) in Q2 2023; revenue $11.1M up from $2.4M.
- Restructuring: 65% headcount reduction (~300 roles), sale of Lexington facility, $75M annual cash burn cut including $50M debt retirement.
- Cash $524M as of June 30, expected to fund operations through end 2027.
- FDA granted RMAT designation for AMT-130 in Huntington's; interim data showed dose-dependent slowing of disease progression and reduced NfL.
- Patient screening started for three new Phase I/II trials (AMT-260 mTLE, AMT-191 Fabry, AMT-162 SOD1 ALS); enrollment expected Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024010529/0001558370-24-010529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024010529/qure-20240801x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer